These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 10650796)

  • 1. Preoperative high type I collagen degradation marker ICTP reflects advanced breast cancer.
    Keskikuru R; Kataja V; Kosma VM; Eskelinen M; Uusitupa M; Johansson R; Risteli L; Risteli J; Jukkola A
    Anticancer Res; 1999; 19(5C):4481-4. PubMed ID: 10650796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum concentrations of type I collagen carboxyterminal telopeptide (ICTP) and type I procollagen carboxy-and aminoterminal propeptides (PICP, PINP) as markers of metastatic bone disease in breast cancer.
    Tähtelä R; Thölix E
    Anticancer Res; 1996; 16(4B):2289-93. PubMed ID: 8694558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Type I collagen metabolites as tumor markers in patients with lung carcinoma.
    Kobayashi T; Gabazza EC; Taguchi O; Risteli J; Risteli L; Kobayashi H; Yasui H; Yuda H; Sakai T; Kaneda M; Adachi Y
    Cancer; 1999 May; 85(9):1951-7. PubMed ID: 10223235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated preoperative serum ICTP is a prognostic factor for overall and disease-free survival in breast cancer.
    Keskikuru R; Bloigu R; Risteli J; Kataja V; Jukkola A
    Oncol Rep; 2002; 9(6):1323-7. PubMed ID: 12375042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type I collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer. Comparison to CEA, CA 15-3, PSA and bone scintigraphy.
    Zissimopoulos A; Stellos K; Matthaios D; Petrakis G; Parmenopoulou V; Babatsikou F; Matthaiou E; Theodosiadou E; Hountis P; Koutis C
    J BUON; 2009; 14(3):463-72. PubMed ID: 19810140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum type I collagen degradation markers, ICTP and CrossLaps, are factors for poor survival in lung cancer.
    Ylisirniö S; Sassi ML; Risteli J; Turpeenniemi-Hujanen T; Jukkola A
    Anticancer Res; 1999; 19(6C):5577-81. PubMed ID: 10697621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical usefulness of cross-linked N-telopeptide of type I collagen (NTx) as a bone metastatic marker in patients with prostate cancer--comparison with serum PICP, PINP and ICTP].
    Kobayashi Y; Ochi M; Tokue A
    Hinyokika Kiyo; 2000 Dec; 46(12):869-72. PubMed ID: 11211802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Procollagen-I, collagen telopeptide I, CEA, CA 15-3 as compared to bone scintigraphy in patients with breast cancer].
    Zissimopoulos A; Petrakis G; Stellos K; Baziotis N
    Hell J Nucl Med; 2006; 9(1):60-4. PubMed ID: 16617400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validity of bone marker measurements for monitoring response to bisphosphonate therapy with zoledronic acid in metastatic breast cancer.
    Aktas B; Kasimir-Bauer S; Lehmann N; Kimmig R; Tewes M
    Oncol Rep; 2013 Jul; 30(1):441-7. PubMed ID: 23604361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of serum KL-6, a mucin-like glycoprotein, as a tumor marker for breast cancer.
    Ogawa Y; Ishikawa T; Ikeda K; Nakata B; Sawada T; Ogisawa K; Kato Y; Hirakawa K
    Clin Cancer Res; 2000 Oct; 6(10):4069-72. PubMed ID: 11051258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical usefulness of blood PICP, PINP and ICTP concentrations as bone metastasis markers in prostate cancer patients].
    Kobayashi Y; Tokue A
    Nihon Rinsho; 1998 Aug; 56(8):2072-6. PubMed ID: 9750510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Type I and III collagen metabolites as predictors of clinical outcome in epithelial ovarian cancer.
    Santala M; Simojoki M; Risteli J; Risteli L; Kauppila A
    Clin Cancer Res; 1999 Dec; 5(12):4091-6. PubMed ID: 10632345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer.
    Ylisirniö S; Höyhtyä M; Mäkitaro R; Pääakkö P; Risteli J; Kinnula VL; Turpeenniemi-Hujanen T; Jukkola A
    Clin Cancer Res; 2001 Jun; 7(6):1633-7. PubMed ID: 11410500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical picture of bone metabolism in breast cancer patients with bone metastases.
    Berruti A; Torta M; Piovesan A; Raucci CA; Orlandi F; Panero A; Dogliotti L; Angeli A
    Anticancer Res; 1995; 15(6B):2871-5. PubMed ID: 8669881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aggressive breast cancer leads to discrepant serum levels of the type I procollagen propeptides PINP and PICP.
    Jukkola A; Tähtelä R; Thölix E; Vuorinen K; Blanco G; Risteli L; Risteli J
    Cancer Res; 1997 Dec; 57(24):5517-20. PubMed ID: 9407961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.
    Pollmann D; Siepmann S; Geppert R; Wernecke KD; Possinger K; Lüftner D
    Anticancer Res; 2007; 27(4A):1853-62. PubMed ID: 17649784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postoperative PINP in serum reflects metastatic potential and poor survival in node-positive breast cancer.
    Jukkola A; Bloigu R; Holli K; Joensuu H; Valavaara R; Risteli J; Blanco G
    Anticancer Res; 2001; 21(4B):2873-6. PubMed ID: 11712779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer.
    Noguchi M; Noda S
    J Urol; 2001 Sep; 166(3):1106-10. PubMed ID: 11490307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis.
    Koizumi M; Takahashi S; Ogata E
    Anticancer Res; 2003; 23(5b):4095-9. PubMed ID: 14666607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor markers in breast cancer monitoring should be scheduled according to initial stage and follow-up time: a prospective study on 859 patients.
    Gion M; Peloso L; Mione R; Vignati G; Fortunato A; Saracchini S; Biasioli R; Gulisano M; Cappelli G
    Cancer J; 2001; 7(3):181-90. PubMed ID: 11419026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.